

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|------------------------------------|---------------------------|----------------------|-------------------------|------------------|--|
| 09/689,343 | 10/12/2000 | Romualdas Vaisvila | NEB-181 | 7976 | |
| 28986 | 7590 03/19/2002 | | | | |
| NEW ENGI | NEW ENGLAND BIOLABS, INC. | | | EXAMINER | |
| 32 TOZER ROAD BEVERLY, MA 01915 | | | GUZO, DAVID | | |
| | | | ART UNIT | PAPER NUMBER | |
| | | | 1636 | | |
| | | | DATE MAILED: 03/19/2002 | 5 | |

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademask Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

| APPLICATION NO./ | FILING DATE | FIRST NAMED INVENTOR / | ATTORNEY DOCKET NO. |
|------------------|-------------|-------------------------|---------------------|
| CONTROL NO. | | PATENT IN REEXAMINATION | |
| | | | |

EXAMINER

ART UNIT PAPER

5

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

- SEE ATTACHMENT -




Art Unit: 1636

Attachment

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures and on the attached Raw Sequence Listing Error Report.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo whose telephone number is (703) 308-1906. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.



Art Unit: 1636

Application/Control Number: 09/689,343

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding or relating to attachments to this Office Action should be directed to Patent Analyst Zeta Adams whose telephone number is (703) 305-3291.

David Guzo March 18, 2002

DAVID GUZO

Application No.

09/689343

MOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING OF MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

| 1 - 1.825 day 15, | . This application clearly fails to comply with the requirements of 37 CFR 1.821 Applicant's attention is directed to these regulations, published at 1114 OG 29, 1990 and at 55 FR 18230, May 1, 1990. |
|-------------------|--|
| | . This application does not contain, as a separate part of the disclosure on opy, a "Sequence Listing" as required by 37 CFR 1.821(c). |
| 3 submitte | . A copy of the "Sequence Listing" in computer readable form has not been ed as required by 37 CFR 1.821(e). |
| o£ 37 C | . A copy of the "Sequence Listing" in computer readable form has been submitted. , the content of the computer readable form does not comply with the requirements FR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw e Listing." |
| | . The computer readable form that has been filed with this application has been obe damaged and/or unreadable as indicated on the attached CRF Diskette Problem A substitute computer readable form must be submitted as required by 37 CFR |
| | . The paper copy of the "Sequence Listing" is not the same as the computer e form of the "Sequence Listing" as required by 37 CFR 1.821(e). |
| Other: | |
| Applic | ant must provide: |
| Listing | An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or |
| For a | 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) Lestions regarding compliance with these requirements, please contact |

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400